The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.

The present disclosure is related to the fields of biology, molecular biology, genetics, microbial fermentation, alcohol production and the like. The present compositions and methods relate to yeast strains comprising genetic modifications that results in modified yeast strains thereof comprising enhanced stress tolerance. Certain embodiments of the disclosure are therefore related to compositions and methods for increasing the efficiency of alcohol production using such modified yeast strains in fermentation reactions/processes.

Described herein are devices and methods for increasing the production of steviol glycosides, which have industrial and economic value. The steviol glycosides produced by the devices and methods disclosed herein do not require the ultra purification that is common in conventional or commercial methods and do not have a bitter aftertaste, making them better suited as flavor-enhancing additives to food, pharmaceutical, and nutritional supplement products.

Described is a method for the incorporation of formaldehyde into biomass comprising the following enzymatically catalyzed steps (1) condensation of pyruvate with formaldehyde into 4-hydroxy-2-oxobutanoic acid (HOB); (2) amination of the thus produced 4-hydroxy-2-oxobutanoic acid (HOB) to produce homoserine; (3) conversion of thus produced homoserine to threonine; (4) conversion of the thus produced threonine into glycine and acetaldehyde or acetyl-CoA; (5) condensation of the thus produced glycine with formaldehyde to produce serine; and (6) conversion of the thus produced serine to produce pyruvate, wherein said pyruvate can then be used as a substrate in step (1).

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

The disclosure provides methods of making gene-edited plants that are resistant to downy mildew, such as plants with reduced expression of homoserine kinase (HSK), 2-oxoglutarate-Fe(II) oxygenase (2OGO), or both. The disclosure further provides methods of making gene-edited modified plants that are cold tolerant, such as plants with reduced expression of MYB14. In some examples, CRISPR/Cas methods are used, wherein the plants include a mutated HSK, 2OGO, and/or MYB14 gene resulting in reduced expression and/or gene activity. Plants generated using the methods are provided. Such plants can include other desirable traits. HSK, 2OGO, and/or MYB14 nucleic acid and protein molecules are provided, as are gRNAs specific for HSK, 2OGO, or MYB14 and vectors containing such.

Fermented milk, containing 0.8 g or more of dephosphorylated casein per 100 g of the fermented milk. Dephosphorylated milk, containing dephosphorylated casein. A method for manufacturing fermented milk, including: (a) fermenting raw material milk in a presence of a protein phosphatase and (b) fermenting raw material milk enzyme-treated with the protein phosphatase.

The present disclosure provides recombinant microorganisms and methods for the anaerobic production of 2,4-furandicarboxylic acid from one or more carbon sources. The microorganisms and methods provide redox-balanced and ATP positive pathways for co-producing 2,4-furandicarboxylic acid with ethanol and for co-producing 2,4-furandicarboxylic acid with ethanol and 1-propanol. The method provides recombinant microorganisms that express endogenous and/or exogenous nucleic acid molecules encoding polypeptides that catalyze the conversion of a carbon source into 2,4-furandicarboxylic acid and that coupled the 2,4-furandicarboxylic acid pathway with an additional metabolic pathway.

The present invention relates to a Streptococcus thermophilus strain, wherein the strain is galactose-fermenting, wherein the strain carries a mutation in the DNA sequence of the glcK gene encoding a glucokinase protein, wherein the mutation inactivates the glucokinase protein or has a negative effect on expression of the gene, and wherein the strain carries a mutation in the promoter region of the GalK gene encoding a galactokinase protein.

It is an object of the present invention to provide, for instance, a method for evaluating a function, such as transforming potential, of multiple different genes of interest, and a method capable of evaluating drug sensitivity of a subject having each gene of interest. The present invention relates to, for instance, a method for evaluating multiple different genes of interest, comprising the steps of: integrating, into host cell genomic DNA, polynucleotides each comprising a tag sequence and a gene of interest or a fragment thereof linked to the tag sequence; mixing a plurality of different host cells having the different polynucleotides integrated therein; culturing the mixed host cells; extracting the genomic DNA from the cultured host cells; quantifying each of the polynucleotides in the extracted genomic DNA based on the tag sequence; and determining a relative cell count of each of the host cells having the respective polynucleotides after the culturing, based on the quantified values for the polynucleotides.